We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Allon Updates Progress of Pivotal Phase 2/3 Clinical Trial
Product News

Allon Updates Progress of Pivotal Phase 2/3 Clinical Trial

Allon Updates Progress of Pivotal Phase 2/3 Clinical Trial
Product News

Allon Updates Progress of Pivotal Phase 2/3 Clinical Trial

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Allon Updates Progress of Pivotal Phase 2/3 Clinical Trial"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Allon Therapeutics Inc. has issued an update on the progress of the pivotal Phase 2/3 clinical trial that is evaluating the Company's lead neuroprotective drug candidate davunetide as a potential treatment for progressive supranuclear palsy (PSP), a rapidly-progressing and fatal degenerative brain disease.

Gordon McCauley, Allon's President and CEO, said the trial has enrolled approximately 50% of the 300 patients specified in the protocol. Enrollment began in the fourth quarter of 2010.

The trial is being conducted under a Special Protocol Assessment (SPA) granted by the United States Food and Drug Administration (FDA), which ensures that the agreed clinical trial design meets the FDA's expectations for a pivotal study.

"Our progress is right on track with our estimate to complete enrollment by the end of 2011 and to report data about a year later," said McCauley.

McCauley continued, "The pace of enrollment is a testament to the patients, caregivers, investigators, and advocacy groups who have been tremendous partners, and who certainly hope this trial will generate data necessary for marketing approval of davunetide as a treatment for PSP."

McCauley also said the trial's Data Safety and Monitoring Board (DSMB) recently approved the continuation of the trial. A DSMB is an independent group of clinical experts with the primary responsibility of monitoring the safety and well-being of subjects and to assure scientific integrity of the study.

A DSMB is independent of the company and the clinical investigators, who are blinded from the safety and efficacy data until all treatment has been completed.